MedTech Watchlist: Small-Cap Names to Watch (April 2026)
The medtech sector is holding its ground in 2026, driven by a convergence of AI integration, point-of-care diagnostics, and interventional oncology gaining real clinical momentum. Small-cap names are beginning to move with it, as clinical updates, regulatory milestones, and early commercial wins attract attention from investors who follow the science closely.
Here are a few names standing out right now.
Intelligent Bio Solutions (NASDAQ: INBS)
INBS recently completed a key clinical study for its fingerprint-based drug screening system, and the technology is worth understanding. It is non-invasive, requires no blood or urine sample, and delivers results from a single fingerprint. That distinction matters in large, compliance-driven markets like workplace testing, law enforcement, and rehabilitation settings.
The next step is FDA submission. Clearance would open access to a market that has long relied on more invasive, logistically complex alternatives. Revenue is growing, international traction is emerging, and the regulatory catalyst is visible on the horizon. This is what early-stage medtech setup looks like before the broader market pays attention.
Delcath Systems (NASDAQ: DCTH)
Delcath’s liver-focused cancer therapy was recently added to European clinical guidelines, and that development should not be underestimated. Guideline inclusion places a therapy directly in front of treating physicians, lending institutional credibility and creating a pathway for broader adoption over time.
The broader thesis here is interventional oncology: treating cancer locally, with greater precision, and with less systemic toxicity than traditional systemic therapies. Delcath is one of the more clinical names on this list, but the signal coming out of Europe is meaningful.
Butterfly Network (NYSE: BFLY)
Butterfly just received FDA clearance for an AI-powered ultrasound tool focused on women’s health. The platform is handheld and portable, designed specifically for point-of-care environments where access to traditional imaging is limited or delayed.
This is directionally where medtech is moving: lower cost, broader access, and faster clinical decision-making, particularly in underserved settings. The convergence of AI and diagnostic hardware is no longer theoretical, and Butterfly continues to be a visible example of how that plays out commercially.
Personalis (NASDAQ: PSNL)
Personalis has already made a move, but it remains worth tracking. The company is focused on liquid biopsy and cancer monitoring, with technology designed to detect disease earlier and measure treatment response in real time. Upcoming data readouts and continued adoption in minimal residual disease testing could sustain momentum for investors who followed it into the move.
This watchlist reflects where medtech innovation is concentrating: non-invasive diagnostics, AI-assisted tools, targeted cancer therapies, and care delivery moving outside the hospital setting. These are not fully de-risked stories. Most remain early stage, capital needs are real, and execution will separate the names that matter from those that do not.
But this is where the activity is. And where early institutional attention tends to begin.
